Healthcare [ 7/13 ] | Biotechnology [ 82/163 ]
NASDAQ | Common Stock
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines.
The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions.
It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.
The company was incorporated in 1995 and is headquartered in Hayward, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 13, 24 | -1.64 Decreased by -925.00% | -0.78 Decreased by -110.26% |
| Feb 13, 24 | -2.64 Decreased by -1.22 K% | -0.39 Decreased by -576.92% |
| Nov 13, 23 | -2.76 Decreased by -487.23% | -0.51 Decreased by -441.18% |
| Sep 21, 23 | -2.83 Decreased by -356.45% | -3.23 Increased by +12.38% |
| May 15, 23 | -0.16 Increased by +60.00% | -0.20 Increased by +20.00% |
| Feb 13, 23 | -0.20 Increased by +66.10% | -0.11 Decreased by -81.82% |
| Nov 10, 22 | -0.47 Increased by +24.19% | -0.18 Decreased by -161.11% |
| Sep 2, 22 | -0.62 Decreased by -8.77% | -0.28 Decreased by -121.43% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 6.00 K Decreased by -88.89% | -4.28 M Increased by +4.06% | Decreased by -71.32 K% Decreased by -763.48% |
| Dec 31, 23 | 0.00 Decreased by -100.00% | -6.80 M Decreased by -30.43% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by -100.00% | -5.95 M Decreased by -6.21% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 7.00 K Decreased by -72.00% | -4.66 M Increased by +13.62% | Decreased by -66.59 K% Decreased by -208.50% |
| Mar 31, 23 | 54.00 K Increased by +12.50% | -4.46 M Decreased by -44.34% | Decreased by -8.26 K% Decreased by -28.30% |
| Dec 31, 22 | 14.00 K Decreased by -44.00% | -5.21 M Decreased by -8.11% | Decreased by -37.23 K% Decreased by -93.05% |
| Sep 30, 22 | 472.00 K Increased by +23.01 K% | -5.61 M Decreased by -11.12% | Decreased by -1.19 K% Increased by +99.52% |
| Jun 30, 22 | 25.00 K Increased by +1.15 K% | -5.40 M Decreased by -34.80% | Decreased by -21.58 K% Increased by +89.22% |